Canaccord lowered the firm’s price target on Biodesix (BDSX) to $2.50 from $3.50 and keeps a Buy rating on the shares. The firm said its target decrease reflects multiple headwinds including tariffs, funding uncertainty, recession fears, and China.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDSX:
- Biodesix Announces Board Member Resignations
- Biodesix, Inc. Reports Strong Growth Amid Financial Challenges
- Positive Outlook for Biodesix: Buy Rating Supported by Salesforce Improvements and Revenue Growth Opportunities
- Biodesix: Strong Financial Performance and Positive Growth Outlook Justify Buy Rating
- Biodesix: Strong Growth and Promising Future with Buy Rating from Kyle Mikson CFA